Representatives from the merged companies went to Interphex in New York this week, where the updated BioPharma-Reporter.com on integration that has taken place so far and shared their thoughts on growing biopharma demand for single-use suppliers.
Ken Frank, president of Pall’s biopharma business, told us that: “Over the years ATMI has developed a very strong single-use portfolio, both in the downstream space for mixers, but also heavily in the upstream space…which is a big complementary technology for Pall.
“Most of our single-use technologies are focused in the downstream space.”
This was echoed by Mario Philips, who served as senior VP of Lifesciences at ATMI, who added that: “It’s clear if you look at our booth here we are bringing a more complete offering to single-use customers and that is really where the market is going.”
“Going forward I think the market is more interested in having a more complete offering from the upstream to the final fill” he continued.
Philips also noted that attending Interphex as a single organisation just three weeks after the merger completed shows that the newly formed team is already working well together.
Much of the focus of Pall’s attendance has been the impact ATMI has had on its single-use business. However, while this type of technology may now be “mainstream,” there will always be room for stainless steel systems said Frank.
“There is always going to be a space for stainless steel. If you are a large single product factory then stainless steel still makes since.”
“But,” Frank continued “single-use brings flexibility. You can begin operations much more quickly and you probably need less infrastructure. So single-use is better suited to certain kinds of producers” citing CMOs or firms that conduct manufacturing for clinical trials as examples.